Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PG-011

Small molecule · developed by Prime Gene Therapeutics Co.

Phase 3 Most advanced trial

PRME Developer

1 Registered trials

What is PG-011?

PG-011 is an investigational small-molecule drug studied in Seasonal Allergic Rhinitis, SAR.

At a glance

Also known as: Pumecitinib nasal spray
Drug type: Small molecule
Therapy area: Ear, nose & throat
Developer: Prime Gene Therapeutics Co., Ltd. (PRME)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07146126	Phase 3	Seasonal Allergic Rhinitis	Not yet recruiting	PRME

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

SARSeasonal Allergic Rhinitis

More from Prime Gene Therapeutics Co.

PG-011Gel Phase 3 PG-033 Phase 1 PM359 Phase 1/2 PM577a Phase 1/2 Pumecitinib Phase 2

Sources

ClinicalTrials.gov NCT07146126

Updated Oct 3, 2026. Something wrong or missing? Report it on the PRME page.

Follow PRME, the company behind PG-011

See PRME's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRME catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z